Virus type | Virus name | Product name | Research and development unit | Coded substances | Delivery systems | Delivery site | ClinicalTrials.gov identifier | Phase | Research progress | Publications |
---|---|---|---|---|---|---|---|---|---|---|
RNA viruses | CHIKV | mRNA-1388(VAL-181388) | Moderna | CHKV-IgG | LNP | Intravenous injection | NCT03325075 | I | Completed | - |
CHIKV | mRNA-1944 | Moderna | CHKV-IgG | LNP | Intravenous injection | NCT03829384 | I | Completed | [21] | |
hMPV、PIV3 | mRNA-1653 | Moderna | Membrane-anchored fusion glycoproteins of hMPV and PIV3 | - | - | NCT03392389 | I | Completed | - | |
hMPV、PIV4 | mRNA- 1653 | Moderna | Membrane-anchored fusion glycoproteins of hMPV and PIV4 | - | - | NCT04144348 | I | In test | [143] | |
H7N9 Influenza virus | VAL-339851(mRNA-1851) | Moderna | H7N9 HA | LNP | Intramuscular injection | NCT03345043 | I | Completed | [91] | |
H10N8 Influenza virus | VAL-506440(mRNA-1440) | Moderna | H10N8 HA | LNP | Intramuscular injection/Intradermal injection | NCT03076385 | I | Completed | [92] | |
Seasonal Influenza Virus | mRNA- 1010 | Moderna | H1N1, H3N2 HA, Influenza B virus HA | – | Intramuscular injection | NCT04956575 | I/II | Completed | - | |
Rabies | CV7201 | Curevac | Rabies virus G protein | LNP | Intradermal injection | NCT02241135 | I | Completed | [95] | |
Rabies | CV7202 | Curevac | Rabies virus G protein | LNP | Intramuscular injection | NCT03713086 | I | Completed | [22] | |
Rabies | GSK3903133A | GSK | Rabies virus G protein | LNP | _ | NCT04062669 | I | Test completed, analysis not yet completed | - | |
RSV | mRNA-1345 | Moderna | – | LNP | _ | NCT04528719 | I | In test | - | |
SARS-COVID-2 | CVnCoV | Curevac | Spike (S) glycoprotein | LNP | Intramuscular injection | NCT04652102 | III | Completed | [75] | |
SARS-COVID-2 | BNT162a1/BNT162b1/BNT162b2/BNT162c2 | BioNTech/Pfizer | Spike (S) glycoprotein | LNP | Intramuscular injection | NCT04380701 | I/II | In test | - | |
SARS-COVID-2 | BNT162b2 | BioNTech/Pfizer | Spike (S) glycoprotein | LNP | Intramuscular injection | NCT04588480 | I/II | Completed | [144] | |
SARS-COVID-2 | mRNA-1273 | Moderna | Spike (S) glycoprotein | LNP | - | NCT04470427 | III | Completed | [145] | |
Zika | mRNA-1893 | Moderna | preM-E with JEV leading sequence | Lipid nanoparticles V1GL | _ | NCT04064905 | I | Completed | - | |
Zika | mRNA-1325 | Moderna | prM-E | LNP | _ | NCT03014089 | I | Completed | - | |
Retrovirus | HIV | iHIVARNA-01 | Massachusetts General Hospital、National Institute of Allergy and Infectious Diseases (NIAID) | HTI | DCs | Inguinal Intra-inguinal injection | NCT02413645 | I | Completed | [146] |
HIV | iHIVARNA-01 | Massachusetts General Hospital、National Institute of Allergy and Infectious Diseases (NIAID) | HTI | DCs | Intradermal injection | NCT02888756 | II | Completed | [147] | |
HIV | – | Massachusetts General Hospital | Gag And Nef | DCs | Intradermal injection | NCT00833781 | I/II | Completed | [146] | |
HIV | mRNA-1644 | Moderna/IVA | eOD-GT8 60mer | LNP | Intramuscular injection | NCT05001373 | I | In test | - | |
DNA viruses | HCMV | mRNA-1647/mRNA-1443 | Moderna | mRNA-1647: gB, PC pentameric complex; mRNA-1443: pp65 | LNP | _ | NCT03382405 | I | Completed | - |
HCMV | mRNA-1647 | Moderna | gB, PC pentameric complex | LNP | _ | NCT04232280 | II | Completed | - | |
HPV | BNT113 | BioNTech | E6 and E7 | LNP | Intravenous injection | NCT05448885 | II | In test | [113] |